REGN Stock Analysis: Buy, Sell, or Hold?
REGN - Regeneron Pharmaceuticals Inc
$612.50
2.56 (0.42%)
▲
5d:
+0.06%
30d:
-5.73%
90d:
-16.42%
BUY
HIGH Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 07, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.1/10
Get Alerted When REGN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: REGN trading at deep discount. Market pricing in -8.3% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: REGN trading at deep discount. Market pricing in -8.3% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$965.63
Based on 4.0% avg growth
INTRINSIC VALUE TODAY
$599.58
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: REGN is currently trading at $612.50, which is considered slightly low relative to its 30-day fair value range of $600.89 to $653.00. From a valuation perspective, the stock is trading at a discount (Forward PE: 12.7) compared to its historical average (16.5). Remarkably, the market is currently pricing in an annual earnings decline of 8.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, REGN is in a strong downtrend. The price is currently testing key support at $594.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $833.31 (+36.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, REGN is in a strong downtrend. The price is currently testing key support at $594.90. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $833.31 (+36.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$600.89 -
$653.00
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.0% below Wall St target ($833.31)
Trading Range Analysis
30-Day Trading Range
$600.89 -
$653.00
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$594.90
Resistance Level
$638.95
Current Trend
Strong Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.73
Wall Street Target
$833.31
(+36.0%)
Revenue Growth (YoY)
19.0%
Earnings Growth (YoY)
-7.2%
Profit Margin
29.6%
Valuation Discount vs History
-8.3% cheaper
PE vs Historical
12.7 vs 16.5
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.3%
(market-implied from PE analysis)
1-Year Target
$561.66
(-8%)
2-Year Target
$515.04
(-16%)
3-Year Target
$472.30
(-23%)
3-Yr Target (if PE normalizes)
(PE: 13→17)
$612.00
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 4.0%)
$1178.92
(+93%)
Base:
(SPY PE: 12.7, Growth: 4.0%)
$689.24
(+13%)
Bear:
(PE: 10.8, Growth: 4.0%)
$585.85
(-4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (15x PE), but valuation improves significantly next year (13x PE) as earnings recover.
Trailing PE: 14.88 | Current EPS (TTM): $40.99
Bull Case
$787.34
(+29%)
Analyst growth 17.4%, PE expands to 16.4
Base Case
$715.77
(+17%)
Market implied 17.4%, PE stable at 14.9
Bear Case
$414.76
(-32%)
Severe decline -20.0%, PE contracts to 12.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 12.7 to 16.5
Stabilization Target:
$793.68
(+29.6%)
PE Expansion Potential:
+29.6%
Share & Embed Analysis
Last updated: June 23, 2026 9:02 AM ET
Data refreshes hourly during market hours. Next update: 10:02 AM
Data refreshes hourly during market hours. Next update: 10:02 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is REGN showing a specific setup today?
Insider Activity (6 Months)
2
Buys
5
Sells
Net
INSIDERS SELLING
Recent Transactions
Huda Y Zoghbi
SELL
1638 shares
2026-02-19
Julia Letlow
BUY
2026-02-12
Arthur F Ryan
SELL
100 shares
2026-02-09
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$436 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 69 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 58 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 52 HOLD |
Advanced REGN Option Strategies
Professional options setups generated by AI based on today's REGN price and gamma walls.
